MannKind Corp. announced Friday that Hakan Edstrom has stepped down as President and CEO.
Edstrom was appointed to the position in January, when founder Alfred Mann announced his retirement and transition to a new role as executive chairman of the company.
Previously, Edstrom had served as president and COO of MannKind since 2001.
After a decade of research and development, and clinical trials on its diabetes treatment Afrezza – replacing insulin injections with an inhaler – MannKind signed a deal with Paris-based distributor Sanofi last year after it received FDA approval.
Sales have been an uphill climb since first going to market and MannKind’s stock has steadily dropped.
One of the hurdles for the treatment approach has been to get insurance companies to cover the inhaler; they tend to find the old prick with a needle method cheaper to cover.
Also, because the inhaler consists of a dry powder a lung test is mandatory before prescription, six months after and every year after that making Afreeza very restrictive for diabetes sufferers tired of looking for a fresh place to stick themselves with a needle each time they need insulin.
Sanofi has a lot of work to do to educate and market the new medical approach.
Lastly, MannKind, after sinking more than $1 billion in development, is only set to receive 35 percent of the net profits from sales, rather than gross, in its deal with Sanofi affecting the stock value.
A committee of the board will commence an immediate search for a successor CEO.
